Please assess the completion status of the following clinical trial:

Trial Title: Treating Multiple Sclerosis With Sirolimus, an Immune System Suppressor

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Relapsing-remitting MS~* Evidence of demyelination on magnetic resonance imaging (MRI) scan~* Expanded Disability Status Scale (EDSS) score between 0 and 6~* Nonresponsive to beta-interferon or Glatiramer acetate therapy~* Discontinuation of beta-interferon or Glatiramer acetate therapy within 1 month prior to study entry~* Willing to use acceptable methods of contraception~Exclusion Criteria:~* Primary progressive MS~* Prior treatment with immunosuppressants~* Steroid therapy within 1 month prior to study entry~* Evidence of active infection or cancer~* Heart or hematologic dysfunction~* High levels of lipids in the blood~* Use of lipid-lowering agents~* History of cirrhosis or liver disease requiring treatment~* History of hepatitis B or C~* Active cytomegalovirus infection~* Kidney disease requiring treatment~* Active lung disease~* Diabetes~* Hyperthyroidism~* HIV infection~* Tuberculosis~* History of alcohol or drug abuse within 6 months prior to study entry~* Claustrophobia or inability to undergo MRI~* Pregnancy or breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 58 Years
- Healthy Volunteers: f

Study Arms:
- sirolimus (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).